Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial.

医学 奥沙利铂 福克斯 卡培他滨 结直肠癌 肿瘤科 内科学 随机对照试验 临床终点 化疗 新辅助治疗 阶段(地层学) 癌症 外科 临床试验 乳腺癌 古生物学 生物
作者
Lars Henrik Jensen,M Kjaer,Finn Ole Larsen,Niels Henrik Holländer,Hans B. Rahr,F. Pfeffer,Laura V. Diness,Jan Lindebjerg,Søren Rafael Rafaelsen,Torben Frøstrup Hansen,Signe Timm,Inger Marie Løes,Ismail Gögenür,Kim Wedervang,Fahimeh Andersen,Lone Petersen,Elinor Bexe Lindskog,Laurids Østergaard Poulsen,Olav Dahl
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:41 (17_suppl): LBA3503-LBA3503 被引量:9
标识
DOI:10.1200/jco.2023.41.17_suppl.lba3503
摘要

LBA3503 Background: Locally advanced colon cancer presents a therapeutic challenge regarding improving survival and minimizing side effects by optimizing the timing of surgical and systemic treatments. Neoadjuvant chemotherapy is a widely accepted approach in numerous cancers as it aims to eliminate micrometastases and reduce tumor size. Our study aimed to assess the impact of neoadjuvant chemotherapy on locally advanced colon cancer compared to standard initial surgery. Methods: This was a randomized, controlled, phase III clinical trial. Patients aged 18 years or older with biopsy-proven colon cancer were eligible for inclusion if staged as T4 or T3 with invasion depth ≥5 mm, N0-2, and M0 according to CT scan evaluation. Patients were randomly assigned to either standard upfront surgery or surgery after neoadjuvant chemotherapy with either 3 cycles of CAPOX (oxaliplatin, capecitabine every 3 weeks) or 4 cycles of FOLFOX (oxaliplatin, 5FU every 2 weeks). Adjuvant chemotherapy was chosen based on the pathological stage of the cancer according to guidelines. The primary endpoint, disease-free survival (DFS), was analyzed on an intent-to-treat basis. The sample size was set at 125 patients per arm, based on a projected increase in two-year disease-free survival from 80% to 90%, with a two-sided significance level of 5%, power of 80%, 3 years of inclusion, 2 years of follow-up, and a 10% drop-out rate. Results: Nine centers in 3 countries included 122 patients in the standard group and 126 patients in the neoadjuvant group from 10/2013 to 11/2021. Forty-four % were female, the median age was 66 years, and 91% had a performance status (PS) of 0, while 9% had a PS of 1. Seventy-three % of the tumors were classified as T3, with a median outgrowth of 11 mm, while 26% were classified as T4 on the baseline CT scan. There were no significant differences in baseline characteristics. The median number of chemotherapy cycles was lower in the neoadjuvant group, 3 (IQR 1-7) vs. 4 (0-8). There were slightly more postoperative complications in the standard group regarding ileus, anastomotic leakage, and length of stay. Postoperatively, more patients in the standard arm had an indication of adjuvant chemotherapy, 88 vs. 72 (p = 0.02). DFS at 2 years was similar in the two arms (p = 0.95, logrank), as was overall survival (OS) (p = 0.95, logrank). Conclusions: Neoadjuvant chemotherapy and standard upfront surgery showed no significant difference in DFS and OS in patients with colon cancer. However, neoadjuvant chemotherapy seemed to have more favorable outcomes in terms of chemotherapy cycles, postoperative complications, and downstaging. CT scan alone may not be sufficient in identifying high-risk patients preoperatively. These findings suggest that neoadjuvant chemotherapy could be considered a viable treatment option for patients with locally advanced colon cancer. Clinical trial information: NCT01918527 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Gaara0504发布了新的文献求助10
刚刚
omelet发布了新的文献求助10
1秒前
大蘑菇炒小蘑菇完成签到,获得积分10
2秒前
GT完成签到,获得积分10
2秒前
可耐的嫣娆完成签到,获得积分10
3秒前
小蘑菇应助小杜采纳,获得10
3秒前
天天快乐应助发嗲的绿柏采纳,获得10
3秒前
英勇的绿海完成签到,获得积分10
4秒前
shan发布了新的文献求助10
5秒前
7秒前
Agan完成签到,获得积分10
8秒前
马化云克完成签到,获得积分10
8秒前
dx完成签到,获得积分10
9秒前
冷酷愚志完成签到,获得积分10
10秒前
科研通AI2S应助Gaara0504采纳,获得10
11秒前
11秒前
颖涵完成签到 ,获得积分10
11秒前
周梦晴发布了新的文献求助30
11秒前
wakkkkk发布了新的文献求助10
11秒前
乐乐应助希波克拉顶采纳,获得10
13秒前
VDV完成签到,获得积分10
13秒前
13秒前
15秒前
爆米花应助啦啦啦啦采纳,获得10
16秒前
葡萄糖发布了新的文献求助20
18秒前
PEI发布了新的文献求助10
18秒前
18秒前
18秒前
搜集达人应助专一的幻莲采纳,获得10
19秒前
医者完成签到,获得积分10
19秒前
香蕉觅云应助博弈春秋采纳,获得10
19秒前
爆米花应助GT采纳,获得10
21秒前
乐观小蕊发布了新的文献求助10
22秒前
22秒前
22秒前
22秒前
wangyu留下了新的社区评论
23秒前
24秒前
hh发布了新的文献求助10
26秒前
27秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976210
求助须知:如何正确求助?哪些是违规求助? 3520366
关于积分的说明 11203088
捐赠科研通 3256965
什么是DOI,文献DOI怎么找? 1798570
邀请新用户注册赠送积分活动 877738
科研通“疑难数据库(出版商)”最低求助积分说明 806516